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Copyright © 200? JCBN Summary Previously, our group reported that sulforaphane (SFN), a naturally occurring
chemopreventive agent from cruciferous vegetables, effectively inhibits the proliferation of KB
and YD-10B human oral squamous carcinoma cells by causing apoptosis. In this study,
treatment of 20 and 40 µM of SFN for 12 h caused a cell cycle arrest in the G2/M phase. Cell
cycle arrest induced by SFN was associated with a significant increase in the p21 protein level
and a decrease in cyclin B expression, but there was no change in the cyclin A protein level.
In addition, SFN increased the p21 promoter activity significantly. Furthermore, SFN induced
p21 protein expression in a nude mouse xenograft model suggesting that SFN is a potent
inducer of the p21 protein in human oral squamous carcinoma cells. These findings show that
SFN is a promising candidate for molecular-targeting chemotherapy against human oral
squamous cell carcinoma.
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Introduction
The cell cycle is highly regulated by a number of check-
point mechanisms, that are essential for the cellular response
to stress including DNA damage and abnormal mitogenic
signals and the cyclins, cyclin-dependent kinases (CDKs)
and CDK inhibitors are important factors that regulate the
cell cycle progression. However, the checkpoint mechanism
does not always work well due to the activation of CDKsSulforaphane Increases p21 protein in Oral Cancer
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and/or inactivation of CDK inhibitors resulting in un-
controlled proliferation which is one of the causes of cancer
[1].
p21 is a CDK inhibitor protein that is essential for cellular
growth, differentiation and apoptosis [2]. Although p21 is
rarely mutated in human tumors, a decrease in p21 protein
expression contributes to the neoplastic progression of many
tumors [3–11]. A number of scientific reports show that
p21 is induced by DNA damage or oncogene expression,
triggering irreversible cell cycle arrest, which facilitates
tumor growth arrest [12–15]. For this reason, induction of
the p21 protein is considered a good strategy for molecular
target therapy.
The use of natural products as chemopreventive agents
has been a major focus for a long time due to their possible
cancer chemotherapeutic activity. Among the many natu-
rally occurring anti-cancer agents, sulforaphane (SFN) has
attracted the attention of cancer investigators. There is accu-
mulating evidences that SFN inhibits the proliferation of
cancer cells both in vitro and in vivo by causing apoptosis
and/or cell cycle arrest [16–21]. Our previous study also
found that SFN induced caspase-dependent apoptosis in
human oral squamous carcinoma cells and a nude mouse
xenograft model [22]. However, the mechanism of the cell
cycle arrest induced by SFN to inhibit the proliferation of
oral cancer cells is not completely understood.
This study confirmed that the treatment with SFN causes
cell cycle arrest of KB and YD-10B human oral squamous
carcinoma cell at the G2/M phase. In addition, it is associated
with a significant increase in p21 protein expression. More-
over, SFN induced p21 protein expression in a nude mouse
xenograft model confirming that SFN activates p21 protein
which contributes to the potent anticancer activity of this
compound.
Materials and Methods
Reagents
Sulforaphane was purchased from Sigma Chemical Co.
(St. Louis, MO). Antibodies for sp1, cyclin A, cyclin B and
actin were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). The p21 antibody was purchased from BD
Pharmingen (San Diego, CA). Propidium Iodide was obtained
by Calbiochem (San Diego, CA), and RNase A was from
Sigma-Aldrich. p21 promoter reporter constructs, pWWP
was provided by Dr. Toshiyuki Sakai (Kyoto Prefectural
University of Medicine, Kyoto, Japan). Lipofectamine 2000
transfection reagent was purchased from Invitrogen
(Carlsbad, CA). Reporter lysis buffer and luciferase reagent
for dual luciferase assays were purchased from Promega
(Madison, WI).
Cell culture and drug treatment
The human oral squamous carcinoma cell line KB
was obtained from American Tissue Culture Collection
(Manassas, VA). Human oral squamous carcinoma cell line
YD-10B was obtained from College of Dentistry, Yonsei
University (Seoul, Korea). KB Cells were maintained in
Dulbecco’s modified essential medium (DMEM; Welgene,
Dae-Ku, Korea) without phenol red and YD-10B cells were
cultured in DMEM/F-12 media (Welgene) containing 5%
fetal bovine serum (FBS) and 10 ml/L of 100X antibiotics
antimycotic solution (Welgene) at 37°C in a humidified
atmosphere of 5% CO2 incubator. For the treatment of
cells with SFN, a stock solution of 40 mM was prepared in
dimethyl sulfoxide (DMSO). An equal number of cells were
seeded in 96-well, 12-well, or 6-well plates and allowed to
attach until plates reached 50–60% confluence, which was
usually observed 24 h after seeding. Cells were treated with
vehicle (DMSO) or compounds of various concentrations
diluted in DMEM without phenol red and supplemented
with 2.5% FBS.
Cell proliferation assay
KB and YD-10B cells were seeded in 12-well plates and
were treated with DMSO and two concentrations of the test
compounds in DMEM containing 2.5% FBS for 12 h. KB
and YD-10B cells were counted to evaluate the effects of
SFN and the vehicle control on the number of viable cells. A
cell count was carried out with a hematocytometer using
equal volumes of cell suspension and 0.4% trypan blue
solution (Sigma Chemical Co.). Each experiment was
carried out in triplicate and results were expressed as
means ± SD for each treatment group.
MTT assay
The MTT assay kit purchased from AMRESCO (Solon,
OH) was used to evaluate the effect of SFN on cell pro-
liferation in KB and YD-10B cells. Cells were seeded in
96-well plates and incubated for 24 h before the treatment
with SFN. After SFN treatment for 12 h, 20 μl of the MTT
solution (2 mg/ml) was added to each well and cells were
incubated for 2 h at 37°C in 5% CO2. The formazan absor-
bance was measured at 560 nm using a microtiter plate
reader (Molecular Devices).
FACS analysis for cell cycle regulation
After treatment with SFN, detached cells (floaters) were
collected by centrifugation and combined with adherent
cells that were released by trypsinization. Cell cycle analysis
was carried out by flow cytometry; cells were fixed in 70%
ethanol overnight at −20°C. After centrifugation, ethanol
was removed and the cells were subsequently stained
with 0.02 mg/ml propidium iodide (PI) and subjected to
DNA content analysis using a FACScan cytometer (BectonJ.-H. Kim et al.
J. Clin. Biochem. Nutr.
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Dickinson, Franklin Lakes, NJ).
Western blot analysis
Cell lysates were prepared using a lysis buffer (20 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM ethylenediamine-
tetraacetic acid (EDTA), 1% Triton X-100, 0.1% sodium
dodecyl sulfate (SDS), 1 mM sodium orthovanadate; 1 mM
phenylmethylsulfonyl fluoride (PMSF), 1 μM leupeptin,
and 1 μg/ml aprotinin). After centrifugation of the lysate at
15,000 g for 20 min, supernatants were recovered, and
protein was quantified by the Bradford protein assay using
a reagent kit from Bio-Rad (Hercules, CA). Protein samples
(20–60 µg) were size-separated by electrophoresis on sodium
dodecylsulfate-polyacrylamide gels under non-reducing
conditions. Separated proteins were electroblotted onto
nitrocellulose membranes. The blot was blocked by incuba-
tion in a blocking buffer (5% skim milk, 10 mM Tris,
pH 7.5, 10 mM NaCl and 0.1% Tween 20) for 1 h at 20°C,
and then incubated with the primary antibody overnight
at 4°C. Incubation with a horseradish peroxidase (HRP)-
conjugated anti-mouse or rabbit secondary antibody was
then carried out at room temperature (RT) for 4 h. Antibody-
bound proteins were detected by the ECL Western blotting
analysis system (Perkin Elmer Life and Analytical Science,
Boston, MA).
Transfection and dual luciferase assay
KB cells were plated in 12-well plates and pWWP
(0.25 g) were transfected by Lipofectamine 2000 reagent
according to the manufacturer’s protocol when plates
reached 50–60% confluence. After 6 h, cells were treated
with complete media containing either vehicle (DMSO) or
SFN for 20–22 h. Cells were then lysed with 100 μl of 1X
reported lysis buffer and 30 μl of cell extract was used for
luciferase assays. Results are expressed as means ± S.D. for
at least three independent determinations for each treatment
group.
Immunohistochemistry
For immunohistochemistry, an EnVisionTM Detection Kit
System (Dako, Glostrup, Denmark), which is based on the
peroxidase-catalysed deposition of biotinylated tyramide was
used. Briefly, 4-μm-thick sections were cut from a paraffin-
embedded tissue block. Sections were then deparaffinized
and hydrated by sequential immersion in xylene and grade
alcohol solution. For antigen retrieval, sections were im-
mersed in a 0.1 M citrate buffer solution at pH 6.0. After
boiling twice in a microwave oven for 5 min, the slides
were cooled to RT and rinsed in phosphate buffered saline
(pH 7.4). The endogenous peroxidase activity was quenched
by treating the specimens with 3% hydrogen peroxide for
5 min at RT. The sections were incubated with primary anti-
bodies for 1 h at 37°C and then incubated with the secondary
antibody for 30 min at RT. Staining was visualized using a
diaminobenzidine (DAB) and counterstained with Mayer’s
hematoxylin. The negative control was performed with the
incubated antibody diluent as a substitute for the primary
antibody.
Nude mouse xenograft assay
Female nude BALB/cAnNCrjBgi-nu mice (6-week-old)
were purchased from Orient Ltd. (Seoul, South Korea), and
maintained in accordance with Institutional Animal Care
Use Committee guidelines. A xenograft was established by
s.c. injection of in vitro cultured KB cells (106 cells/200 ul)
into the flank of mice. Mice were randomized into two
groups of 5 mice/group (2 tumors/mouse). Experimental
animals were treated orally with SFN (50 μg/kg) 3 times/
week (Monday, Wednesday and Friday) for 21 days begin-
ning the day of tumor cell implantation. Control mice
received an equal volume of the vehicle. Tumors were
measured along two diameter axis with calibers to permit
calculation of tumor volume, V = π/6{(D + d) / 2}3, where
D and d were the larger and smaller diameters, respectively.
Statistical significant differences in tumor volume, wet
tumor weight or body weight between control and treated
mice was assessed by Student’s t tests.
Statistical analysis
Statistical significance was assessed using Student’s t
tests. A value of p<0.05 compared with solvent control was
considered statistically significant.
Results
Effect of sulforaphane on KB and YD-10B cell proliferation
The growth-inhibitory effect of SFN was examined
initially by assessing the proliferation efficacy on KB and
YD-10B human oral carcinoma cells using cell counting. As
shown in Fig. 1A and B, SFN significantly reduced the
viability of both cell lines. Treatment with 40 μM SFN
inhibited the cell proliferation of KB and YD-10B cells by
approximately 58% and 46%, respectively. The results of
the cell counting assay were confirmed by estimating the
number of viable cells using an MTT cell proliferation assay.
This assay also showed that SFN inhibits cell viability
(Fig. 1C and D). Based on these results, we confirmed that
SFN has a growth-inhibitory effect on cell proliferation in
KB and YD-10B cells.
Sulforaphane induces the G2/M phase cell cycle arrest
Since SFN inhibits KB cell proliferation, we analyzed
the cell cycle distribution under the SFN-induced growth-
inhibitory conditions using flow cytometry analysis. When
the cells were treated with SFN for 12 h, cell proliferation
was arrested and accumulated mainly in the G2/M phaseSulforaphane Increases p21 protein in Oral Cancer
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(Fig. 2A). The G2/M phase arrested cells were increased
from 28% and 24% in DMSO-treated KB and YD-10B cells
to 54% and 35% in 40 μM of SFN-treated cells, respectively
(Fig. 2B).
Sulforaphane induces CDK inhibitor, p21 protein and its
transactivation
Because, the most of the cells were arrested at the G2/M
phase, experiments were carried out to determine whether
the SFN treatment also affects the expression level of G2/M
phase cell cycle regulatory proteins. KB cells were treated
with 20 μM of SFN for 12 h and the expression of these
proteins (p21, cyclin A and cyclin B) were examined by
western blot analysis. Fig. 3A and B showed a significant
increase in the level of p21 protein expression and the level
of cyclin B expression was significantly reduced by SFN
whereas cyclin A was not changed. Furthermore, SFN
induced the transactivation in KB cells transfected with
pWWP (Fig. 3C). To find whether sp1 protein regulates
p21 protein expression, we evaluated the level of sp1 protein
expression. Unfortunately, sp1 protein was not changed by
SFN compared to control (Fig. 3D). These results suggest
that SFN modulates the expression level of the G2/M phase
cell cycle regulatory proteins and its transactivation in KB
oral carcinoma cells.
Sulforaphane induces p21 protein in nude mouse xenograft
model
Immunohistochemistry detected the level of p21 protein
from the tumor sections and they were obtained from
animals in previous studies which showed that SFN inhibited
oral carcinoma growth in athymic nude mice bearing KB
cells as xenograft [22]. There was markedly increased
immunostaining of p21 protein in oral carcinoma treated
with 50 μg/kg of SFN compared to the tumors from the
vehicle control (Fig. 4).
Discussion
Cruciferous or Brassica vegetables come from the Brassica
genus, including broccoli, Brussels sprouts and cauliflower.
They are a good source of glucosinolates and their hydro-
lysis products, including indoles and isothiocyanates. The
dietary intake of cruciferous vegetables has been associated
with a lower risk of certain types of cancers including
prostate, lung and colorectal cancer in some epidemiological
studies [23–27]. Hence, an examination of the relationships
between cancer risk in humans and phytochemicals specifi-
Fig. 1. Effect of sulforaphane (SFN) on cell proliferation in KB and YD-10B cells. KB cells (A) and YD-10B cells (B) were treated
with DMSO or various concentrations of SFN for 12 h. Cell proliferation was determined by a trypan blue exclusion assay. Cell
viability in KB cells (C) and YD-10B cells (D) was estimated using a MTT assay. The results are reported as the mean ± SD of
three independent experiments. *p<0.05 compared to the control group.J.-H. Kim et al.
J. Clin. Biochem. Nutr.
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cally rich in cruciferous vegetables is expected to help pre-
vent cancer. Among the phytochemicalsin these vegetables,
SFN is the most characterized isothiocyanate compound.
Many studies have reported that SFN is an effective agent
against the proliferation of a variety of cancer cells [22, 28–
30]. It was previously reported that SFN exhibited a signifi-
cant inhibition on the growth of KB and YD-10B cells
with caspase-dependent apoptosis [22]. In this study, it was
found that early-time exposure (12 h) to SFN significantly
decreases the number of viable KB and YD-10B cell growth
in a dose-dependent manner (Fig. 1). On the other hand,
there were no apoptotic events observed in SFN-treated cell
for 12 h. Therefore, other possible mechanisms for how SFN
inhibits the proliferation of oral squamous carcinoma cells
were examined. Several studies on SFN reported that SFN
induces G2/M cell cycle arrest in cancer cells [18, 31, 32].
Therefore, this study examined cell cycle regulation in KB
and YD-10B cells and SFN induced a profound arrest in the
G2/M phase (Fig. 2). These results suggest that the G2/M cell
cycle arrest induced by SFN is a prerequisite for caspase-
dependent apoptosis in these cell lines. However, more
critical experiments will be needed to test this hypothesis.
CDK inhibitors have grown in importance and number
since they were first described and they appear to be
universal inhibitors of cyclin/CDK activity which functions
by forming a complex with the cyclin/CDK to inhibit the
growth of cancer [2, 33,  34]. p21, a CDK inhibitor also
inhibits CDKs. The induction of p21 molecule causes a
number of different cell lines to arrest in both G1 and G2
checkpoint. SFN was reported to induce G2/M arrest in a
variety of cancer cell lines and p21 expression is associated
with G2/M phase cell cycle arrest [31, 35, 36]. Our study
showed that SFN induces the p21 expression and its trans-
activation to induce G2/M phase arrest (Fig. 3). There results
are fully consistent with other studies. We also previously
reported that SFN decreased tumor growth in athymic nude
mice bearing KB cells as xenograft. Fig. 4 shows that p21
was also induced in the tumor sections from the same
animals demonstrating comparable induction of this pro-
apoptotic protein in both in vivo and in vitro tumor models.
The specificity protein (Sp) family recognizes GC-rich or
GT-rich DNA and regulates the promoters of several genes
[37, 38]. The human p21 gene contains six Sp1 binding sites
[39]. Due to close relationship between Sp1 and p21, we
Fig. 2. Effect of SFN on the cell cycle distribution in KB and YD-10B cells. KB and YD-10B cells were treated with DMSO or various
concentrations of SFN for 12 h. Both floating and attached cells were collected and processed for an analysis of cell cycle reg-
ulation as described in “Materials and Methods” (A) Representative histograms of cell cycle distribution in the control and
SFN-treated cells are shown. The data points in the graph are the mean ± SD of three independent experiments in KB cells (B)
and YD-10B cells (C). *p<0.05 compared to control group.Sulforaphane Increases p21 protein in Oral Cancer
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evaluated Sp1 protein expression level in this system.
Unfortunately, Sp1 protein was not affected by SFN indi-
cating that Sp1 is not an upstream protein of p21 (Fig. 3D).
Of several CDK inhibitors, p21 is an important mediator
of cell cycle arrest regulated by tumor suppressor p53 in
response to DNA damage [40]. In addition to being induced
by p53, p21 is also induced by other factors in a p53-
independent pathway [41, 42]. Recently, Traka et al. (2009)
reported that the induction of p21 protein by SFN can be
mediated by Kruppel-like factor 4 (KLF4) in colon cancer
cells and tissues suggesting that KLF4 might be a possible
mediator for p21 protein in this study [43]. Therefore,
current studies are focused on identifying these critical
proteins induced by SFN in oral squamous carcinoma cell
lines to induce p21 protein.
In summary, this study demonstrates for the first time that
SFN inhibit growth and induce G2/M cell cycle arrest in
oral squamous carcinoma cell lines. Moreover, p21 protein
plays an important role in SFN-induced cell cycle arrest.
Therefore, these findings confirm that SFN is a promising
Fig. 3. Effects of SFN on the levels of the proteins involved in the regulation of G2/M transition. (A) immunoblotting for p21, cyclin B
and cyclin A using lysates from control and SFN-treated KB cells. (B) The data points in the graph are the mean ± SD of three
independent experiments. *p<0.05 compared to the control group. (C) Transactivation activity of pWWP (p21 promoter
construct) induced by SFN in KB cells. (D) immunobloting for sp1 protein using lysates from control and SFN-treated KB cells.
Fig. 4. Effects of SFN on the expression level of p21 protein expression in an athymic nude mouse xenograft model. (A) Immunostain-
ing of p21 in tumor tissue samples. Tumor tissue samples from mouse xenografts bearing KB cells were deparaffinized and
immunostained with the p21 antibody as described in Materials and Methods. (B) Immunoreactivity score values of p21 protein
in tumor tissues. 0; negative, 1; weakly positive, 2; moderately positive, 3; strongly positive. *p<0.05 compared to control
group.J.-H. Kim et al.
J. Clin. Biochem. Nutr.
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candidate for molecular-targeting chemotherapy against
human oral squamous cell carcinoma.
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